Open access
Jul 2026
Fatty-acid-based antimiR-23b delivery in the DMSXL model: A potential therapeutic strategy for brain dysfunction in myotonic dystrophy type 1
This study evaluates the therapeutic potential of the lipid-conjugated antimiR-23b, X82108, designed to promote MBNL1/2 upregulation through inhibition of miR-23b, and highlights X82108 as a promising systemic therapy for DM1.
D. Piqueras-Losilla, Andrea García-Rey, Aline Huguet-Lachon et al.
· Cell Reports Medicine · 0 citations